446 reports of this reaction
1.5% of all EZETIMIBE AND SIMVASTATIN reports
#18 most reported adverse reaction
RHABDOMYOLYSIS is the #18 most commonly reported adverse reaction for EZETIMIBE AND SIMVASTATIN, manufactured by Organon LLC. There are 446 FDA adverse event reports linking EZETIMIBE AND SIMVASTATIN to RHABDOMYOLYSIS. This represents approximately 1.5% of all 29,702 adverse event reports for this drug.
Patients taking EZETIMIBE AND SIMVASTATIN who experience rhabdomyolysis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RHABDOMYOLYSIS is a less commonly reported adverse event for EZETIMIBE AND SIMVASTATIN, but still significant enough to appear in the safety profile.
In addition to rhabdomyolysis, the following adverse reactions have been reported for EZETIMIBE AND SIMVASTATIN:
The following drugs have also been linked to rhabdomyolysis in FDA adverse event reports:
RHABDOMYOLYSIS has been reported as an adverse event in 446 FDA reports for EZETIMIBE AND SIMVASTATIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
RHABDOMYOLYSIS accounts for approximately 1.5% of all adverse event reports for EZETIMIBE AND SIMVASTATIN, making it a notable side effect.
If you experience rhabdomyolysis while taking EZETIMIBE AND SIMVASTATIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.